betaxolol has been researched along with Reperfusion Injury in 7 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether topical application of flunarizine reduces intraocular pressure (IOP) and acts as a retinal neuroprotectant and to compare the effectiveness of flunarizine with betaxolol and nifedipine at reducing the influx of calcium and sodium." | 3.71 | Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. ( Chidlow, G; Cupido, A; Melena, J; Osborne, NN; Wood, JP, 2002) |
| "Betaxolol was applied topically after the start of reperfusion and its effect was evaluated by morphometry and choline acetyltransferase immunoreactivity of retinas at 7 days after reperfusion." | 1.32 | Betaxolol attenuates retinal ischemia/reperfusion damage in the rat. ( Cheon, EW; Cho, GJ; Choi, WS; Kang, SS; Park, CH; Song, JK; Yoo, JM, 2003) |
| "Betaxolol is a beta-adrenergic blocker but its neuroprotective action is generally thought to be due to its calcium channel blocking properties." | 1.31 | Nitric oxide synthase expression in the transient ischemic rat retina: neuroprotection of betaxolol. ( Cheon, EW; Cho, GJ; Choi, WS; Kang, SS; Park, CH; Song, JK; Yoo, JM, 2002) |
| "Betaxolol was tested to see whether it can attenuate the influence of the glutamate agonists, hypoxia or experimental ischaemia." | 1.30 | In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. ( Carvalho, AL; Cazevieille, C; DeSantis, L; Larsen, AK; Osborne, NN, 1997) |
| "Betaxolol is a beta(1)-adrenergic blocker but its neuroprotective action is generally thought to be due to its calcium channel blocking properties." | 1.30 | Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. ( Bae, JH; Chidlow, G; DeSantis, L; Nash, MS; Osborne, NN; Ugarte, M; Wood, JP, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheon, EW | 3 |
| Park, CH | 3 |
| Kang, SS | 3 |
| Cho, GJ | 3 |
| Yoo, JM | 3 |
| Song, JK | 3 |
| Choi, WS | 3 |
| Wood, JP | 3 |
| Schmidt, KG | 1 |
| Melena, J | 2 |
| Chidlow, G | 3 |
| Allmeier, H | 1 |
| Osborne, NN | 4 |
| Cazevieille, C | 1 |
| Carvalho, AL | 1 |
| Larsen, AK | 1 |
| DeSantis, L | 2 |
| Bae, JH | 1 |
| Ugarte, M | 1 |
| Nash, MS | 1 |
| Cupido, A | 1 |
7 other studies available for betaxolol and Reperfusion Injury
| Article | Year |
|---|---|
Nitric oxide synthase expression in the transient ischemic rat retina: neuroprotection of betaxolol.
Topics: Amacrine Cells; Animals; Betaxolol; Brain Ischemia; Immunohistochemistry; Intraocular Pressure; Male | 2002 |
The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Calcium; Cell Hypoxia; Cell Survival; Cells, Cultur | 2003 |
Change in endothelial nitric oxide synthase in the rat retina following transient ischemia.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Ischemia; Male; Neuroprote | 2003 |
Betaxolol attenuates retinal ischemia/reperfusion damage in the rat.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Choline O-Acetyltransferas | 2003 |
In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent.
Topics: Animals; Betaxolol; Calbindin 2; Calcium; Cell Hypoxia; Cells, Cultured; Chick Embryo; Choline O-Ace | 1997 |
Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Calcium Channel Blockers; | 1999 |
Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Animals; Betaxolol; Calcium; Calcium Channel B | 2002 |